Immunotherapy

Characterization of Long-Term Survivors in TOPAZ-1

March 2023, Vol 4, No 1 — April 4, 2023

Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.

Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.

Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

ICIs as Salvage Therapy for BTCs with KRAS Mutation

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Results are presented from a retrospective analysis of molecular profiles in patients with biliary tract cancers to assess the efficacy of immune checkpoint inhibitors according to KRAS mutation.

Nivolumab with or without Ipilimumab plus SBRT in Pretreated Advanced BTC

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Second-line treatment options for patients with advanced biliary tract cancer are limited. Results from a randomized phase 2 study aimed at evaluating nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic disease are presented.

Immunotherapy

Subscribe Today!

I'd like to receive:

Stay In The Know